India Reports Progress Over EU Drug Ban
This article was originally published in SRA
India has reported progress in discussions with European Union regulators over a ban by the European Commission on hundreds of Indian generic equivalents of off-patent drugs due to testing quality issues.
You may also be interested in...
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.
Prime Minister Narendra Modi’s government has decided to "comprehensively review" India's antiquated drug legislation to take into account the latest medical developments and improve safety, amid complaints about poor-quality manufacturing and products.